Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins by Sollner, Johannes et al.
BioMed  Central
Page 1 of 17
(page number not for citation purposes)
Immunome Research
Open Access Research
Analysis and prediction of protective continuous B-cell epitopes on 
pathogen proteins
Johannes Sollner1, Rainer Grohmann2, Ronald Rapberger1, Paul Perco1,3, 
Arno Lukas1 and Bernd Mayer*1,2
Address: 1emergentec biodevelopment GmbH, Rathausstrasse 5/3, A-1010 Vienna, Austria, 2University of Vienna, Institute for Theoretical 
Chemistry, Dr. Bohrgasse 6, A-1030 Vienna, Austria and 3Medical University of Vienna, Department of Nephrology, Währingergürtel 18-20, A-
1090 Vienna, Austria
Email: Johannes Sollner - johannes.soellner@emergentec.com; Rainer Grohmann - rainer.grohmann@univie.ac.at; 
Ronald Rapberger - ronald.rapberger@emergentec.com; Paul Perco - paul.perco@meduniwien.ac.at; Arno Lukas - arno.lukas@emergentec.com; 
Bernd Mayer* - bernd.mayer@emergentec.com
* Corresponding author    
Abstract
Background: The application of peptide based diagnostics and therapeutics mimicking part of protein antigen is experiencing
renewed interest. So far selection and design rationale for such peptides is usually driven by T-cell epitope prediction, available
experimental and modelled 3D structure, B-cell epitope predictions such as hydrophilicity plots or experience. If no structure
is available the rational selection of peptides for the production of functionally altering or neutralizing antibodies is practically
impossible. Specifically if many alternative antigens are available the reduction of required synthesized peptides until one
successful candidate is found is of central technical interest. We have investigated the integration of B-cell epitope prediction
with the variability of antigen and the conservation of patterns for post-translational modification (PTM) prediction to improve
over state of the art in the field. In particular the application of machine-learning methods shows promising results.
Results: We find that protein regions leading to the production of functionally altering antibodies are often characterized by a
distinct increase in the cumulative sum of three presented parameters. Furthermore the concept to maximize antigenicity,
minimize variability and minimize the likelihood of post-translational modification for the identification of relevant sites leads to
biologically interesting observations. Primarily, for about 50% of antigen the approach works well with individual area under the
ROC curve (AROC) values of at least 0.65. On the other hand a significant portion reveals equivalently low AROC values of <
= 0.35 indicating an overall non-Gaussian distribution. While about a third of 57 antigens are seemingly intangible by our
approach our results suggest the existence of at least two distinct classes of bioinformatically detectable epitopes which should
be predicted separately. As a side effect of our study we present a hand curated dataset for the validation of protectivity
classification. Based on this dataset machine-learning methods further improve predictive power to a class separation in an
equilibrated dataset of up to 83%.
Conclusion: We present a computational method to automatically select and rank peptides for the stimulation of potentially
protective or otherwise functionally altering antibodies. It can be shown that integration of variability, post-translational
modification pattern conservation and B-cell antigenicity improve rational selection over random guessing. Probably more
important, we find that for about 50% of antigen the approach works substantially better than for the overall dataset of 57
proteins. Essentially as a side effect our method optimizes for presumably best applicable peptides as they tend to be likely
unmodified and as invariable as possible which is answering needs in diagnosis and treatment of pathogen infection. In addition
we show the potential for further improvement by the application of machine-learning methods, in particular Random Forests.
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Background
The applicability of peptides for the generation of preven-
tive vaccines, therapeutics and diagnostics is an actively
investigated field. Although historically disfavored the
application of peptides in vaccine design is currently expe-
riencing a renaissance[1]. While the focus is often on T-
cell responses especially the generation of B-cell responses
is of relevance against certain pathogens such as HIV to
prevent initial infection [2]. It is thus not surprising that
since the early days of computational biology scientists
have attempted to predict the relevance of protein
domains and peptides in several areas of application. Ini-
tial hallmarks of the field are represented, among many
others, by work of Hopp and Woods [3,4]. During the fol-
lowing and more recent years various methods and prob-
lems concerning the prediction of continuous B-cell
epitopes have been proposed [5-12]. Recently the usabil-
ity of amino acid scales for the prediction of B-cell
epitopes has been profoundly questioned [13] and com-
mon standards regarding the validation of epitope predic-
tions have been discussed [14].
Generally, B-cell antigenicity predictions should probably
be understood as a measure of the likelihood to develop
antibodies against a particular determinant or part of a
surface, rather than another. In addition, most proposed
classifiers of continuous epitopes are ultimately a com-
posite of accessibility and charge-interaction potential
prediction with a strong focus on delivering a few experi-
mentally applicable peptides rather than an overall com-
plete probability distribution for raising antibodies. In
addition, continuous epitopes make up an undefined but
presumably small part of the complete "epitope space" of
an antigen. This even so when assuming distinct epitopes
rather than a continuous surface and accepting dominant
continuous elements of structural epitopes as continuous
epitopes.
In this study we extend previous work by investigating a
subgroup of continuous B-cell epitopes, namely protec-
tive continuous epitopes. This aspect has to the best of our
knowledge not been systematically tackled so far.
From a biological point of view several principles should
govern the availability and evolutionary behavior of pro-
tective amino-acid sites on proteins. One of the questions
we ask is whether these principles or constraints lead to
signals which can be used for predicting or rather detect-
ing candidate epitopes. We assume that an antibody (and
hence it's epitope) is protective because the function of
the antigen (target protein) is inhibited and the activity of
the organism is thus reduced. Or alternatively because
immunological processes are activated leading to the
destruction of the organism. The prior (protectivity class
I) might most likely be expected in adhesion molecules or
pathogenicity factors like matrix degrading proteases and
toxins.
The second category (protectivity class II) would primarily
refer to downstream events of antibody induced comple-
ment activation such as pore formation and opsonization
leading to phagocytosis. It can be considered likely that
the two mechanisms would often lead to differently char-
acterized epitopes. Consequently as different functional
constraints can be expected separate strategies for detect-
ing them may be required. Basically any protein of high
expression and density on the surface with at least one
good epitope can be the target of class II protectivity. We
define a "good" epitope as a surface area of high interac-
tion potential, shape complementarity to the basic layout
of an antibody [15] and dissimilar to self. Predicting that
class therefore also requires to assess (or estimate) the
density of a protein on the cell during pathogenesis, opti-
mally experimentally or by inference from related organ-
isms. A practically applicable continuous epitope could
then be any exposed, possibly evolutionarily highly varia-
ble loop with an amenable antigenicity and solvent-acces-
sibility profile. Class II protectivity may often be
comparably straightforward to predict as soon as a target
protein has been identified because selection of high scor-
ing B-cell epitope scores often seems to be relatively
straightforward and selection routines primarily falter in
the domain of suboptimal scores as has been indicated by
Sollner and Mayer [9]. However, immunologically sub-
dominant or even cryptic B-cell epitopes can be of special
interest regarding protectivity and inter-strain cross-reac-
tivity [16] and are sometimes consistently immuno-silent
during natural infection [17,18]. As a consequence we
focus on conserved and therefore presumably function-
ally constrained epitopes without post-translational mod-
ifications which still exhibit amenable antigenicity scores.
Regarding the previous definition these epitopes may
often fall into class I of protective continuous epitopes.
Such principles are primarily valid for pathogens already
adapted to the host. Organisms in the process to adapt to
new hosts or receptors can undergo significant alterations
in their antigenic structure as has been demonstrated for
SARS virus [19-21] and HIV [22], respectively.
We speculate that by means of functional constraints cent-
ers of biological activity can exert conserving pressure on
closely associated potential epitopes while less relevant
regions can be more variable. It may also be viable to sug-
gest that conservation of posttranslational modification
patterns may be different when comparing highly variable
exposed loops and sites of functional relevance as modifi-
cations can play a major role in the masking of protective
epitopes [23,24] but may often be undesired near func-
tional centers.Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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As Class II protectivity is to a certain degree already
approached by standard B-cell epitope prediction (the
maximization of antigenicity) and on the other hand
depends on a bioinformatically more elusive factor
(expression levels of pathogen protein) we see reason to
focus on the prediction of conserved, functionally con-
strained epitopes (class I protectivity).
This work assesses in how far correlation between anti-
genicity, variability, post-translational modifications and
protectivity/functional relevance can be put to use in a
predictive model without the availability of 3D data. To
compensate for the lack of 3D data multiple alignments of
selected proteins are harnessed to derive information
regarding the conservation of post-translational modifica-
tion motifs as well as sequence variability per-se. We
believe that understanding evolutionary "movement" of
pathogen proteins allows insights into the importance of
potential epitopes and we interpret such importance as
indicator of protectivity.
Results
Classification into presumably protective or non-protec-
tive epitopes is conducted using three independently
determined parameters: predicted B-cell antigenicity,
sequence variability and conservation of post-transla-
tional modification motifs. As described in the Methods
section used antigenicity, variability and motif-conserva-
tion scores are based on multiple-alignments i.e. each
sequence contributes to a composite value. All values are
determined within 10-mers which slide over the align-
ments and overlap by 9 amino-acids. B-cell antigenicity
and sequence variability are averaged within these 10-
mers. We chose this size to use an intermediate between
common assumptions about sizes of continuous epitopes
(usually between 7 and 15 amino-acids). The maximum
ratio of post-translational modifications over all constitu-
ent alignment columns is used within the same area. In
other words, for the prior two the 10-mer values are calcu-
lated as the averages over the averages calculated from
individual alignment columns. The latter seeks the maxi-
mal ratio of possibly modified amino-acids over all align-
ment-columns in the area because it presumably is most
indicative of actual modifications. An overview over the
major steps in the workflow has been highlighted in fig-
ures 1 and 2.
Antigenicity Classification
Logistic regression models based on PCA of 505 amino acid 
propensity scales
We examined regression models based on 505 amino acid
propensity scales. As described in Methods each of these
scales characterizes amino acid residues regarding specific
properties by assigning a value. From this representation,
the information of 505 amino acid propensity scales was
transformed into 19 principal components applying prin-
cipal component analysis.
Based on these 19 principal components, a logistic regres-
sion model was derived. It is in the following mentioned
as PCA19.
Briefly, a dataset of 197 proteins was obtained by cluster-
ing all BCIPEP sequences with at least 30% identity. This
step removed redundancies potentially biasing validation
procedures. In a second step non-antigenic amino-acids
were randomized (maintaining the original amino-acid
composition) to avoid the misclassification of unknown
epitopes.
Each amino-acid of those proteins was then parameter-
ised using all of the described 19 components. Validation
on the training set by bootstrap analysis in combination
with a logistic regression indicated an AROC value of
0.60.
Validation of antigenicity predictions on an independent dataset
To obtain an unbiased impression of the performance of
the PCA19 classifier compared to an accepted gold stand-
ard such as ABCpred [25] an independent validation-data-
set published by Blythe and Flower was used. To make
methods compatible ABCpred predictions were run with
standard settings except that the threshold was lowered to
0.1. Scores reported for peptides by ABCpred were
assigned to each comprising amino-acid where larger val-
ues superseded the prediction of an overlapping peptide.
AROC values were calculated. Both methods performed
close to random (as is not too astonishing concerning the
findings by Blythe et.al), with AROC values of 0.55 and
0.52 for PCA19 and ABCpred, respectively. These results
are relativated later in this work when using only poten-
tially relevant domains of a protein antigen, indicating
systematic problems of the way B-cell epitope prediction
validation is usually conducted.
Protectivity Analysis and Prediction
Effect of domain-accessibility filtering on protectivity prediction
To assess the effect of domain accessibility filtering (mask-
ing) from protectivity prediction AROC values of the
described linear parameter combination before and after
filtering were compared. Whereas the median AROC over
all protein was determined as 0.56 before masking of pre-
sumably inaccessible trans-membrane or cytoplasmic
domains it increased to 0.65 afterwards. While the AROC
before masking is comparable to the one obtained by anti-
genicity prediction on the Blythe and Flower validation
dataset the improvement to 0.65 strongly indicates the
benefit of the procedure. Domain accessibility filtering
can be considered an aspect of fair evaluation in B-cell
epitope classification as a whole as it can be assumed thatImmunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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The figure shows the first part of the overall workflow applied in this project Figure 1
The figure shows the first part of the overall workflow applied in this project.Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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The figure shows the second part of the overall workflow applied in this project Figure 2
The figure shows the second part of the overall workflow applied in this project.Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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continuous epitopes of accessible domains are more likely
mapped or otherwise reported than others, besides the
protectivity aspect. While it may be argued that inclusion
of Uniprot data into the process adds an aspect of human
intervention we see that many data-sources can and are
used for the annotation of putative ectodomains. Among
those are also experimental data, which is in itself not a
problem for bioinformatical validation strategies as long
as the validation dataset was not engineered to fit these
data particularly well. That is not the case. The domain fil-
ter was simply built by manually collecting different data-
sources according to simple rules as we considered auto-
mated harvesting for 57 proteins and unnecessary effort.
Prediction of protective linear epitopes using a sum-score
To evaluate the prediction of protective linear epitopes a
new validation dataset was generated as described in
Methods and Data. Briefly, the IEDB resource was queried
for pathogen proteins with linear antibody determinants
which lead to a biological effect upon interaction.
In viral polyproteins commonly only the dominant sur-
face proteins were used as could be expected for a newly
sequenced pathogen without in detail knowledge. To
limit predictions to candidate regions (i.e. possibly
immunologically accessible regions) domain accessibility
filtering was applied. To do so domain data regarding
polyproteins, trans-membrane structures or signal-pep-
tides (predicted or experimentally determined) were
taken from UniProt [26] or predicted using the TMHMM
v.2.0 [27] and SignalP 3.0 Servers [28]. Domains which
were not considered relevant for protective B-cell
responses were intracellular domains of trans-membrane
proteins, the first 10 amino-acids of a putative extra-cellu-
lar domain after a trans-membrane region and leader-pep-
tides. Briefly, proteins were completely scored for
antigenicity/protectivity but amino-acid scores in regions
outside domains assumed to be surface exposed were set
to 0 thus leading to a generic classification as non-protec-
tive. Masked amino-acid stretches were still considered for
ROC calculation to reflect the impact of the analysis as a
whole. AROC measures were thus based on completely
scored proteins partially set to 0.
For each amino-acid of proteins in the protectivity dataset
variability and percentage of modifications (ratio of
sequences which carry a modification motif indicating
this specific amino acid versus all aligned sequences)
based on multiple alignments were calculated as
described earlier. Finally the average predicted antigenic-
ity was calculated for each alignment column. Each of the
three sub-scores was then rescaled between 0 and 1 for
easier comparability.
To asses the power of score-combinations antigenicity, 1
– variability and 1 – PTM ratio were summed for all over-
lapping 10-mers where the score was assigned to the cen-
tral amino-acid.
See Table 1 for AROC values of individual proteins using
any of the three sub-scores alone as well as the linear com-
bination (sum score). The last row of the table indicates
the overall AROC when analyzing all unmasked amino-
acids together.
Considering the AROC merged value (resulting from the
concatenation of all putatively accessible domains after
scoring) antigenicity alone outperforms all other scores,
including the combined one. Yet, although Table 1 indi-
cates overall better performance of antigenicity, the distri-
bution of AROC values for individual proteins indicates a
different view. Table 2 shows that for the combined score
fewer proteins fall in the very low AROC area (7 versus 10
are < = 0.35) whereas substantially more (30 versus 21)
fall in the AROC area we considered good (> = 0.65).
Eight of the 57 proteins used for protectivity prediction
are similar or identical to sequences used for training the
PCA19 classifier (as identified using blastp). To evaluate
this bias/contamination the AROC value medians of truly
independent versus dependent (contaminated) proteins
has been listed in Table 2. Interestingly and against expec-
tation contaminated proteins underperform when meas-
ured by median compared to independent entries leading
to the observation that no pre-emptive separation of
shared sequences is necessary in this case. For an overview
of AROC distributions see the histograms in figure 3.
Taken together 25 or 30 (44 or 53%) of 57 investigated
proteins reveal AROC values > = 0.65 depending on
whether contaminated proteins are neglected or not. This
population is characterised by mean and median AROC
values of 0.77 and 0.74, respectively. We interpret this as
a roughly 50% probability that protectivity prediction will
significantly enhance selection of peptides for the stimu-
lation of protective immune responses for a particular
protein, given that a relevant protein has been identified
beforehand. We also want to point out that overall up to
65% of proteins show AROC values < = 0.35 or > = 0.65.
Synthesis Score
As described in Methods a "Synthesis Score" representing
the number of peptides required for likely experimental
success is a relevant readout concerning minimization of
experimental cost. For vaccine design it is crucial to limit
the number of synthesized peptides which enter experi-
mental validation to a practically feasible amount. How
many peptides can be synthesized depends on budget and
resources as well as ethical considerations regarding the
number of lab-animals, entities which are tied to theImmunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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Table 1: protectivity AROC values for individual proteins separately derived from predictions based either on antigenicity, 1 – 
modifications or 1 – variability as well as a combined (sum) score for individual proteins
protein function protein antigenicity modifications variability combined
attachment/fusion P11224 0,51 0,15 0,42 0,15
attachment/fusion 2327073 0,77 0,69 0,77 0,77
attachment/fusion 1930067 0,83 0,51 0,64 0,65
attachment/fusion P09592 0,66 0,77 0,57 0,74
RNA encapsidation 13559809 0,62 0,48 0,50 0,46
enzyme/secreted 
cytolysin
P13128 0,45 0,47 0,43 0,45
RNA encapsidation 37724690 0,29 0,74 0,26 0,67
toxin/translocation/
binary-toxin
Q46221 0,42 0,28 0,10 0,11
attachment/capsid P30129 0,77 0,35 0,07 0,29
DNA replication 138881 0,31 0,31 0,14 0,13
toxin P01558 0,41 0,49 0,29 0,41
host evasion/IgG 
binding
13622466 0,88 0,61 0,86 0,76
attachment/fusion 116774 0,60 0,40 0,26 0,41
enzyme/host 
evasion
15644702 0,68 0,55 0,65 0,63
enzyme/protease P10845 0,91 0,55 0,60 0,77
attachment/fusion P03449 0,59 0,50 0,45 0,49
transport P13794 0,82 0,75 0,64 0,81
attachment/fusion P08669 0,63 0,58 0,67 0,70
attachment (?) Q02938 0,82 0,60 0,54 0,73
enzyme/protease/
tissue invasion
30260755 0,18 0,80 0,94 0,85
unknown function P13403 0,55 0,75 0,51 0,73
unknown function P13664 0,46 0,68 0,91 0,70
unknown function 42374894 0,62 0,58 0,64 0,66
toxin/translocation/
binary-toxin
P13423 0,59 0,62 0,22 0,56
unknown function 14162008 0,23 0,23 0,11 0,08
attachment/fusion P59594 0,57 0,45 0,59 0,52
transport P16567 0,47 0,51 0,20 0,31
unknown function 13621499 0,35 0,30 0,65 0,36
attachment (?) 13622014 0,27 0,46 0,16 0,39
unknown function 15675130 0,64 0,96 0,73 0,92
unknown function 13622584 0,63 0,56 0,72 0,65
unknown function 790646 0,98 0,83 0,25 0,95
host evasion/
resistance to 
phagocytosis (?)
P26948 0,62 0,57 0,61 0,70
unknown function P21206 0,54 0,52 0,43 0,58
enzyme 153640 0,35 0,88 0,80 0,87
transport 13623184 0,55 0,70 0,65 0,69
attachment/fusion P35253 0,56 0,45 0,27 0,38
host evasion/
resistance to 
phagocytosis/toxin
P55128 1,00 0,40 0,54 0,73
attachment/fusion P03524 0,54 0,73 0,65 0,73
host evasion/
superantigen
P06886 0,90 0,68 0,37 0,80
toxin P0A0L2 0,43 0,54 0,49 0,46
host evasion/
superantigen
P01552 0,34 0,59 0,38 0,53
attachment 97812 0,80 0,57 0,80 0,73
attachment/fusion P27662 0,66 0,43 0,72 0,50
host evasion/
resistance to 
phagocytosis
P12379 0,44 0,47 0,35 0,41Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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number of proteins (antigens) to be screened as well as
available time. To provide such a measure we defined the
size of peptides to be synthesized as 17-mers (a size com-
monly used by us) and the minimal overlap with protec-
tive epitopes to call it a hit as five amino-acids. Selected
peptides could overlap, but each new epitope had to be
centered on a hitherto uncovered amino-acid. These cen-
tral amino acids were selected by maximizing the
described sum score of antigenicity + (1-variability) and
(1-maximal modification ratio).
Following this procedure we determined how many pep-
tides had to be selected per protein to provide a likely
working selection for at least 50% of screened proteins.
The presented combination method required six peptides
to be selected compared to eight for random picking. This
compares to five versus eight peptides when only the 30
proteins with AROC > = 0.65 were looked at. Note that
random picking of central-amino acids was also restricted
to the regions not filtered out by domain-exclusion to
warrant fairness in the comparison.
By synthesizing and validating a maximum of six pep-
tides, on average every second potentially protective pro-
tein can be expected to be the source of likely quite
host evasion/
resistance to 
phagocytosis
P02977 0,32 0,37 0,25 0,33
transport 13621681 0,64 0,41 0,54 0,46
toxin/peptidase/
binary-toxin
P15917 0,51 0,22 0,65 0,21
attachment/fusion P33478 0,71 0,61 0,69 0,69
unknown function P19597 0,85 0,87 0,61 0,86
attachment/fusion P07946 0,71 0,46 0,31 0,53
attachment/fusion Q05320 0,43 0,54 0,18 0,38
attachment/RNA 
encapsidation
P03308 0,88 0,86 0,71 0,82
attachment/fusion/
neuraminidase
O89343 0,19 0,88 0,31 0,71
attachment/fusion P05769 0,93 0,97 0,91 0,97
attachment/RNA 
encapsidation
P08617 0,86 0,82 0,86 0,90
attachment/fusion Q69091 0,89 0,69 0,45 0,78
merged (contaminated) 0,66 0,62 0,62 0,65
mean non-contaminated 0,60 0,56 0,52 0,59
mean contaminated 0,60 0,57 0,51 0,59
median non-
contaminated
0,62 0,56 0,56 0,65
median contaminated 0,55 0,59 0,51 0,63
Proteins highlighted in bold are markedly homologous or identical to sequences used for the training of the PCA19 antigenicity classifier. Values 
derived from those proteins are denoted as "contaminated". The last five rows compare overall (global) classification performances of concatenated 
(merged) proteins as well as mean and median values between individual parameters and the combined score. Note that "merged" does not mean 
averaged and is thus biased by the length of individual proteins.
Table 1: protectivity AROC values for individual proteins separately derived from predictions based either on antigenicity, 1 – 
modifications or 1 – variability as well as a combined (sum) score for individual proteins (Continued)
Table 2: The table lists AROC performance of protectivity classifications for individual proteins based on different parameters
AROC antigenicity modification variability combined
proteins where AROC 
< = 0.35
10 7 16 7
proteins where AROC 
> = 0.65
21 19 16 30
AROC median non-
contaminated
0.62 0.56 0.56 0.65
AROC median 
contaminated 
0.55 0.59 0.45 0.63
Note that measured by the AROC median non-contaminated proteins unexpectedly seem to perform better than contaminated sequences. The 
combined classifier yields higher median AROC values than classifications based on individual parameters. Possibly more important, the number of 
proteins with AROC values > = 0.65 is substantially higher when comparing the combined score (protein count 30) with the best single score 
antigenicity (protein count 21).Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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conserved, optimally unmodified, continuous and protec-
tive or at least functionally altering epitopes.
Analysis of feature correlation in protective epitopes
To assess the relationship of antigenicity, variability and
modifications Pearson correlation-coefficients were calcu-
lated. After domain-filtering all distinct (non-overlap-
ping) protective regions were analyzed separately to
obtain an idea whether a common trend could be identi-
fied. In summary, overall average and median correlation
were not significant between antigenicity, variability and
modification ratio (generally < = 0.30 and > = -0.18). For
each combination a subset of epitopes showed high corre-
lation, however. Results have been summarized in Table
3.
Note that no pair of features shows significant positive or
negative correlation for more than 30% of the total
The figure shows the distribution of AROC values for protectivity predictions solely based on antigenicity, PTM (post transla- tional modifications), variability as well as the sum score of the three Figure 3
The figure shows the distribution of AROC values for protectivity predictions solely based on antigenicity, PTM (post transla-
tional modifications), variability as well as the sum score of the three.
Table 3: The table lists numbers of protective epitopes exhibiting negative or positive feature association when considering all six 
possible combinations of antigenicity, modification percentage, variability and evolutionary constraint index (ECI)
antigenicity modification variability ECI
antigenicity 0/110 33/14 31/26 26/23
modification - 0/110 22/27 19/21
variability - - 0/110 15/31
ec --- 0 / 1 1 0
Note that like for the prediction of protectivity the used modification and variability scores (features) have been used as 1-value, so actual 
associations have to inverted as well. Each field in the table contains a pair of numbers where the first and second indicate the number of epitopes 
associated with a Pearson coefficient of < = -0.5 and > = 0.5, respectively. High numbers therefore indicate a strong degree of feature association.Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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number of 110 considered epitopic regions. However, for
all pairs of sub-scores strong positive and negative associ-
ations exist. In the case of antigenicity and variability
more than 50% of analyzed epitopes show strong correla-
tion between the two, but at practically equal numbers
positive and negative association. This means that roughly
25% of epitopes are either markedly antigenic and con-
served or non-antigenic and variable. Furthermore
another 25% are markedly antigenic and variable or non-
antigenic and conserved. Protective epitopes seem to be
tendencially positively correlated considering antigenicity
and conservation of motifs for posttranslational modifica-
tion while variability and the evolutionary constraint
index (ECI) are often negatively associated, as could be
expected. Unfortunately no association between protein
functional class and type of correlation could be detected
(data not shown). Preliminary experiments evaluating the
potential power of the correlation coefficient as a new
parameter for protectivity prediction indicated close to
random performance (data not shown).
The previously described observation that for about 65%
of proteins either substantially good or bad predictive
power can be seen suggests that the described 30% corre-
lated epitopes are distinct sets depending on the parame-
ter-combination. Alternatively it may also be that weaker
correlations than -0.5 and +0.5 can still positively influ-
ence AROC.
Machine Learning models
An unweighted linear combination score is a simple way
to combine parameters without optimizing a model, i.e.
as a first approach strategy or if non independent optimi-
zation dataset exists. To extend this strategy, albeit with-
out the option to analyse the unbiased effect on the entire
protectivity dataset, machine-learning procedures were
applied.
In particular, to analyse the validity of using all three
parameters as well as the relative merit of the sum-score
the protectivity dataset was converted into a format ame-
nable for machine learning procedures such as decision
trees. As described in the Methods section the entire protec-
tivity set of 57 proteins was subjected to domain filtering
to restrict to possibly accessible residues which were then
compiled into the CML set. The class separation baseline
of this set is 93,01%, due to the massive domination of
non-protective residues. Using WEKA standard settings a
C4.5 decision tree achieved 96.12% separation on the
same set.
Because relative merits of machine learning are difficult to
assess on strongly biased datasets such as CML, balanced
and stratified training and validation sets (MTS and MVS,
respectively) were randomly sampled from CML to make
independent validation possible. Using the training set
(MTS) and again applying C4.5 different parameter com-
binations were assessed. Results can be seen in table 4 and
figure 4. The decision tree algorithm was applied because
for single parameters this should basically be a search for
the entropically optimal class-split whereas for parameter
combinations also non-linear relationships (particularly
the presence of distinct groups) can be captured. The table
shows that each parameter contributes significantly and
the best model comprises all three attributes as well as the
sum-score as a fourth attribute. Independent of variability
alone shows the best class-separation among individual
parameters. Interestingly PTM alone yields no improve-
ment over random classification while the combination
with the remaining features significantly boots its impact.
Table 4: The table shows the class separation measured by 10-fold stratified cross-validation using a C4.5 decision tree learner on the 
training dataset (MTS). In each row a different combination of input parameters was used as indicated by X (present) in the last four 
columns. Separation baseline for this dataset is 50%
Nr %sep TN FP FN TP FPrate TPrate score antigen PTM var
a 57.78 1086 759 799 1046 0.41 0.57 X ---
b 54.58 1242 603 1073 772 0.33 0.42 -X- -
c 49.86 920 925 925 920 0.50 0.50 -- X -
d 60.08 1382 463 1010 835 0.25 0.45 --- X
e 70.41 1399 446 646 1199 0.24 0.65 XXXX
f 63.47 1607 238 1110 735 0.13 0.40 - XXX
g 65.42 1337 508 768 1077 0.28 0.58 X-X X
h 65.28 1259 586 695 1150 0.32 0.62 XX - X
i 66.18 1263 582 666 1179 0.32 0.64 XXX -
j 56.02 1298 547 1076 769 0.30 0.42 -X X-
k 61.00 1446 399 1041 804 0.22 0.44 -X-X
l 63.82 1520 325 1010 835 0.18 0.45 -- X X
Column abbreviations: %sep (% class separation), score (sum score), antigen (PCA19 derived antigenicity score), PTM (post-translational 
modifications), var (variability score), TPrate (True Positive rate) and FPrate (False Positive rate).Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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To assess the performance of a somewhat more sophisti-
cated machine-learning technique validation using the
validation set and cross-validation are compared in table
5 for a C4.5 tree and a Random Forest. Obviously there is
much potential for improvement over a single decision
tree as the Random Forest achieves a class separation
power of up to 83–84% compared to 70–73% using a sin-
gle tree.
Analysis of the C4.5 tree generated from the validation set
indicates the merit of all four attributes including the
sum-score as an additional parameter as all four were
incorporated by the algorithm (tree not shown). In addi-
tion the resulting tree is astonishingly complicated (109
leaves) when considering that only four parameters were
used, again indicating the existence of different clusters.
Preliminarily, these groups may well be interpreted as dis-
tinct epitope signatures pointing towards different types
of protective epitopes. In other words, different but recog-
nizable epitope profiles should be considered. It also
becomes obvious that a single unweighted combination
score has its merit but is outperformed by variability alone
and both of them by decision tree based multi-parameter
models, at least in the stratified data representation. Also,
the sum-score proves to be an important additional com-
ponent in the decision models as can be seen by the
increase from 63% class separation to 70% class separa-
tion by inclusion of this extra feature.
Exemplary prediction of a protective continuous epitope
To exemplarily show how the described methods may be
used for the prediction of continuous, protective epitopes
a recently published relevant epitope on Borrelia burgdor-
feri OspC has been used [29]. The protein was selected
because it was the first to show up in a new IEDB query for
functionally altering epitopes and because it shows no sig-
nificant homology to any protein in the protectivity data-
set. Figure 5 indicates the experimentally determined
epitope (fat red bar) together with a masked signal pep-
tide (fat gray bar) together with results from three predic-
tive methods. The top-most plot shows the sum-score
which does not obviously correlate strongly with the
epitope. Even after removal of isolated, positively pre-
dicted amino-acids (which can be considered as noise)
both the C4.5 prediction and the Random Forest predict
amino acids inside the 15-mer epitope. As the Random
Forest performed best during validation it is used for the
selection of five 17-mer peptides each centered on a clus-
ter of a least two amino-acids. One of these peptides cov-
ers more than 50% of the protective epitope. While the
proposed methods do not excel on this independently
chosen protein five selected peptides may be enough to
sufficiently cover the relevant site. As a remark it is also of
interest that the consensus prediction of the C4.5 tree and
the Random forest would obviously reduce the selection
to two peptides with the same epitope coverage.
Discussion
This work describes the generation of a novel B-cell classi-
fier based on the logistic regression of amino acid param-
eters derived from principal component analysis of a
commonly used parameter database. We extend the clas-
sical application of antigenicity classifiers from the predic-
tion of continuous B-cell epitopes to the prediction of
protectivity by introducing measured variability and pre-
dicted modification patterns into the concept.
Table 5: The table compares the performance of a decision tree derived using the C4.5 algorithm and a Random Forest, both 
generated with standard parameters. Ten-fold stratified cross-validation (on MTS) and validation on an independent protectivity 
validation set (MVS) are compared
C4.5 Random Forest
% sep FPrate TPrate % sep FPrate TPrate
Cross-validation 70.41 0.24 0.65 83.39 0.15 0.82
Validation-set 73.64 0.26 0.73 84.27 0.15 0.83
Column abbreviations: %sep (% class separation), FPrate (False Positive rate) and TPrate (True Positive rate).
The figure shows the ROC plot of C4.5 decision trees used  to determine the relevance of individual parameters and  parameter combinations for the prediction of protectivity Figure 4
The figure shows the ROC plot of C4.5 decision trees used 
to determine the relevance of individual parameters and 
parameter combinations for the prediction of protectivity. 
For details on the obtained classifications please see table 4.Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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We could show that validation on the data-set by Blythe
and Flower revealed close to random performance for
both the gold standard ABCpred as well as for PCA19,
although our method exhibited marginally better per-
formance in comparison. This result is clearly relativated
as we could show far better performance on a different
dataset when considering only potentially relevant
domains.
In detail, to assess the benefit of excluding presumably
irrelevant domains from the prediction of protective con-
tinuous determinants a manual selection of protein
regions was created based on standard bioinformatical
tools. For this selection we used a curated set of 57 pro-
teins with known protective or otherwise functionally
altering, continuous epitopes. On this compilation pro-
tectivity prediction using PCA19 in combination with var-
iability and modification likelihood performed
significantly better after domain-accessibility filtering as
measured by AROC values, while without filtering per-
formance was comparable (although again slightly better)
to antigenicity validation results on the Blythe et.al valida-
tion-set. Even when disregading eight proteins which con-
taminate the validation process due to similarity with the
PCA19 training data the difference persists and is even
enhanced.
Another primary observation is the gross variance in
AROC values observed for various proteins. Approxi-
mately 65% of sequences exhibited AROC values < = 0.35
or > = 0.65, indicating a pattern substantially different
from random noise. It may be wise to investigate the per-
formance on a per-protein or per-epitope basis and to reg-
ister how many percent of known, distinct sites were
found with high reliability. That may help to avoid an
averaging effect leading to the underestimation of the pre-
dictive power of classifiers. If a method performs well on
every second protein or on certain epitopes that may be
sufficient for many practical applications in the life-sci-
ences field. This is especially so where high throughput is
involved. Interestingly no correlation between the func-
tional category of a protein or pathogen class (bacterial or
viral) and the AROC could be established, indicating a
more complex situation than just two types of epitope
each associated with a distinct functional class.
By determining the number of theoretically required syn-
thetic peptides to achieve satisfying protectivity in a vac-
cine or mAb approach we conclude that up to six peptides
would be required to achieve success in every second pro-
tein. Such success naturally requires the existence of pro-
tective, largely conserved and possibly unmodified
epitopes.
We also want to point out that the selected validation set
presumably represents a combination of differently well
mapped proteins. In addition, each of these can contain
one or several protective B-cell epitopes of both class I and
II. As we tried to detect only one of these in the set,
neglecting the other, validation is skewed against our
method. It may also be good to remember that calculated
AROC values are averaged over entire proteins, not dis-
tinct epitopes.
The application of machine-learning procedures poten-
tially combines the prediction of different epitope classes
and allows an estimation of the information content in
the data. A Random Forest model achieved 83% class sep-
aration in an equilibrated model, pointing towards the
potential to significantly improve upon the single-score
method.
Although the selection of pathogen proteins relevant for
the stimulation of protective immune-responses can be
enhanced by bioinformatics that is a topic distinct from
the prediction of likely protective epitopes on these anti-
gens [30,31]. By combining in-silico ranking of likely pro-
tective targets and likely protective peptides from these
targets completely automatized screening for applicable
peptides is possible. Although methods do exist now for
both aspects of in silico protectivity screening caution is
still necessary. For example, the method published by
Doytchinova and Flower predicts 95% of the proteins in
our dataset as protective antigens (or at least antigens).
On the other hand 65% of the proteome of Staphylococ-
cus aureus COL (1727 of 2618 proteins) are also pre-
dicted to be relevant antigens which although possible
The figure plots the classification results of the C4.5 tree (in  blue), the Random Forest (in green) as obtained during vali- dation in comparison to the signal peptide (fat grey bar) and  the published continuous epitope (fat red bar) Figure 5
The figure plots the classification results of the C4.5 tree (in 
blue), the Random Forest (in green) as obtained during vali-
dation in comparison to the signal peptide (fat grey bar) and 
the published continuous epitope (fat red bar). On top the 
values for the sum-score are plotted. The last line indicates 
the hypothetical selection of five 17-mers (slim red bars) 
based on the Random Forest prediction as it performed best 
during cross-validation.Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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seems to be a very high number suggesting a higher false
positive rate than approximated by validation procedures
in the publication. On the other hand all proteins are
ranked by a score, so an order of predicted relevance is
available, in our view essential for practical use. Unfortu-
nately 701 proteins would be selected to cover all four
proteins for which S. aureus protectivity data is available
in the IEDB and which have close homologues also in
strain COL (fibronectin-binding protein A and B, entero-
toxin B and enterotoxin type A), yet not all may be
required for a protective immune response and others
may contain unmapped or discontinuous epitopes [32].
These findings indicate that several predictive methods
and experimental data should be combined when select-
ing candidates for the generation of protective immune
responses.
Our work solely focuses on the prediction of candidate
peptides after such a selection has taken place, independ-
ent whether by means of experimental data, literature
mining or purely bioinformatical/biological considera-
tions.
Conclusion
We can show that prediction of protective or at least func-
tionally relevant continuous B-cell epitopes can be effi-
ciently done for approximately 50% of 57 analyzed
proteins of pathogen origin. By minimizing sequence var-
iability and probability of post-translational modification
it can also be assumed that selected peptides are particu-
larly suited for vaccine or monoclonal antibody genera-
tion. Exclusion of rationally selected domains strongly
enhances the prediction of protective sites, indicating the
relevance of a filtering step to restrict to immunologically
likely accessible regions. Furthermore, analysis of correla-
tion between variability, conservation of modification
profiles and predicted antigenicity shows different and
opposed categories of correlation thus indicating the
existence of distinct epitope types. At this point it is diffi-
cult to verify or falsify our basic assumption of the two-
class nature of protective epitopes. On the other hand the
high percentage of epitopes with either positive or nega-
tive feature correlation indicates the existence of at least
two types. Also, decision tree based models significantly
outperform the single score-model pointing towards
more complex relationships as well as possibly several dis-
tinct epitope signatures.
Future paths may lie in the detailed unraveling of param-
eter-associations and the utilization of more sophisticated
classification methods such as regression trees for the
assessment of biological relevance and protectivity in the
selection of peptides for biotechnological application, as
indicated by initial Random Forest classification.
Methods
Generation of a B-cell epitope (antigenicity) classifier
The set of 505 unique amino acid propensity scales taken
from the AAINDEX database [33] forms a 20 × 505
descriptor matrix of rank 19. Calculation of sequence
properties from propensity scales can be expressed as a
matrix multiplication of the amino acid sequence in
matrix representation with the descriptor matrix. Hence,
the resulting property matrix is of rank 19 as well, corre-
sponding to 19 linearly independent vectors. From this
only 19 coefficients plus the intercept can be estimated in
regression models. Therefore Principal Component Anal-
ysis (PCA) was employed to transform the propensity
scales from the 505-dimensional space to a 19-dimen-
stional subspace spanned by all 19 principal components
with non-zero Eigenvalues, comparable to how parameter
reduction has been done before [34,35]. The 20 × 505
descriptor matrix was centered and scaled to unity vari-
ance before the application of PCA. The full information
contained in the original 20 × 505 descriptor matrix is
retained, because no component is omitted. From this
PCA-transformation, a new 20 × 19 descriptor matrix was
built. These 19 PCA-derived propensity scales were used
in turn to calculate sequence characteristics for the data
set. The values were averaged over a sliding window of
nine amino acids. Logistic regression employing the logit
function was used to build models for the classification of
single amino acid residues as epitopic or non epitopic.
In order to estimate the generalization error, bootstrap
validation was employed. Error estimates were acquired
from out-of-bag validation – i.e. using those residues that
are not part of the bootstrap sample as validation data. 50
replicates were calculated for the validation of each inves-
tigated model.
The Blythe and Flower dataset
For validation of antigenicity classifiers a published anti-
genicity validation set by Blythe et.al (2005) was used.
The list of 48 proteins we used from the dataset (because
the mapping was clear) can be found in the supplemen-
tary material [see Additional file 2]. The data itself can be
requested from Blythe et.al.
Capturing protein variability
To numerically represent variability of a protein at a cer-
tain amino acid position an information-entropy measure
has been applied. For each protein where variability
should be determined the sequence was BLASTed against
the non-redundant protein database (nr) and hits were
selected manually. The aim was to choose a diverse but
not too diverse set of sequences to optimally represent the
degree of evolutionary freedom of each amino acid posi-
tion. Those proteins were downloaded and multiplyImmunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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aligned using clustalw. For each alignment column a var-
iability value was calculated as follows:
Randomly draw 100 samples of size 30 (i.e. 100 times 30
amino acids which is a combination with repetition) from
each column, independent of how many sequences have
been aligned. That way the evaluation should be less
dependent on the number of homologues as for some
proteins only five elements can be found whereas for oth-
ers hundreds are available. Determine the most abun-
dantly found amino-acid in the column. Then calculate
the Shannon-entropy weighted by the EMBOSS [36]
EBLOSUM variant of the BLOSUM62 [37] substitution
scores between each amino acid and the most abundant
one in the column. After averaging over all 100 samples to
obtain the mean variability the final variability score for
each alignment column computes as
where f(j) is the score at alignment column j, fx is the fre-
quency of the most abundant letter x in column j, fi is the
frequency of letter i in column j and Wix is the substitution
weight between letters i and x. For each alignment varia-
bility scores are independently rescaled between 0 and 1.
The variability score ultimately used for protectivity scor-
ing is 1 – rescaled f(j).
Note that each individual gap is regarded as a new charac-
ter which occurs only once (thus extending the 20 letter
alphabet to a potentially high number leading to the per-
ception of strongly gapped positions as highly variable).
As an independent strategy an evolutionary constraint
index (ECI) was calculated for each alignment column.
This constraint is essentially the difference between the
standard Shannon entropy and the entropy after reducing
the amino acid alphabet according to the same substitu-
tion matrix as above. Briefly, amino acid identities were
grouped as follows: E < = E, D, Q, K, R ; I < = I, L, M, V; Y
< = Y, W, F, H; S < = S, T, A. Other amino-acids remained
ungrouped. The ECI is primarily discussed when parame-
ter correlations are analyzed.
Posttranslational protein modifications
To predict posttranslational protein modifications
PROSITE [38] patterns were used. In particular we consid-
ered patterns PS00001, PS00002, PS00003, PS00004,
PS00005, PS00006, PS00007, PS00008, PS00009,
PS00010, PS00012, PS00013, PS00294, PS00409. All
sequences in the previously created multiple alignments
were searched for the occurrence of these patterns. For
each hit the amino acid putatively carrying the modifica-
tion was marked and for each column in the alignment
the ratio m of modified amino-acids was calculated. As for
sequence variability the value used for protectivity scoring
is  1-m. The advantage of using motif predictions on
aligned sequences is the possibility to derive the degree of
conservation of the motif. Combined with the assump-
tion that conserved motifs of post-translational modifica-
tion are more reliable and do otherwise carry a high false
positive rate this increases the weight of the prediction.
Data for training antigenicity classifiers
A reference data set was generated from the antibody
binding site repository BCIPEP [39]. This database holds
a collection of experimentally determined B-cell epitopes.
The BCIPEP data set is highly redundant with plenty of
entries showing relation to more than one source protein.
To realize a non-redundant data set, homologue proteins
of this collection were grouped. Members of two different
groups differed by at least 30% in sequence identity. After
this partitioning, the number of epitopes with length
between 6 to 30 amino acids that could be localized on
each protein was determined. Finally, the proteins bearing
the largest number of epitopes were selected as the repre-
sentative for their group. This procedure leads to a diverse
set of protein sequences with experimentally determined
immunogenic regions for each protein.
This data set holds in total 197 proteins with an average
length of 449 amino acids. The prevalence of amino acids
being part of an epitope is 7.6%. The mean length of an
epitope is 16 residues. Out of the 197 proteins 60 origi-
nate from bacteria, 55 from viruses, 14 from fungi, 11
from human, 3 from allergens, and 54 from other sources
(e.g. eukaryotic parasites). The data set holds in total 401
continuous epitopes, i.e. about 2 epitopes per protein.
Since no systematic epitope mapping of all the proteins in
the data set has been performed, categorizing sequence
regions as non-antigenic is problematic, as these could be
categorized false negative. Epitopes classified as non-
epitopes do exist, yet it is problematic to discern whether
those are the results of organism or individual (i.e.
responses varying from individual to individual) or yet
other biases. We chose to declare the non-defined regions
of our reference dataset as non-epitopes. Regions not part
of an epitope were randomized while maintaining the
average amino-acid frequency of BciPep. The resulting
was used for training B-cell epitope classifiers.
Each amino-acid functioned as the central amino acid of
a 9-mer (peptide), inheriting its class (antigenic or non-
antigenic) to the peptide which was then used for param-
eterization and training/validation. Nine-mers were used
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due to the desire to use an intermediate between common
assumptions about sizes of continuous epitopes (usually
between 7 and 15 amino-acids).
Antigenicity scores for alignments
Each sequence in the generated multiple alignments was
independently scored for its antigenicity using the PCA19
classifier. PCA19 classification resulted in the assignment
of an antigenicity value for each amino acid in the multi-
ple alignment with the exception of the flanking 5 amino
acids due to a window effect. For each alignment column
overall antigenicity was calculated as the average anti-
genicity over the corresponding amino acids of individual
sequences.
Data for validating predictions of protectivity
Proteins with known B-cell determinants were down-
loaded from the "The Immune Epitope Database and
Analysis Resource" (IEDB) [40,41]. The IEDB allows filter-
ing by various criteria. We applied the following step-wise
exclusion filters to obtain a protectivity-related dataset:
1. 'Assay Group' = 'Ab binding leading to biological activ-
ity' (767 proteins remained)
2. 'Epitope Structure Chemical Type' = 'Peptide/Protein'
(735 proteins remained)
3. 'Epitope Source Species' must be defined (679 proteins
remained)
4. Exclude linear fragments shorter than 3 and linear frag-
ments longer than 50 aa and structural epitopes (381 pro-
teins remained)
5. 'Qualitative Measurement' = 'Positive' (235 proteins
remained)
6. Remove 'Epitope Source Species' = 'Homo Sapiens'
(227 proteins remained)
7. Remove identical rows and obvious redundancies or
identical sequences in different strains of the same organ-
ism. (184 proteins remained).
8. Remove entries from non-pathogens (including patho-
genic plants).
SRC6129 and SRC6623 were removed because no Uni-
prot or GenBank Ids were specified. A neutral protease (gi
30260755) of Bacillus anthracis str. Ames was manually
added from a literature source [42]. All proteins were then
clustered and identified groups multiply aligned using the
standard tools blastclust and clustalw, respectively.
Epitopes of all sequences present in the alignment were
manually mapped to the homologous sequence where the
fewest remapping steps were necessary, or where all
epitopes could be represented as can be the case for large
deletions or proteins with precursor variants. The process
is thus similar to the one applied at the Los Alamos
National Laboratory HIV database where all reported
epitopes are remapped to the reference strain HXB2 [43].
After removal of all redundancies and impractically short
proteins 57 entries (31785 amino acids), with an average
peptide coverage (and thus protectivity prevalence) of
7.25% remained, which are from now on referred to as
"protectivity dataset". It has to be cautioned that the func-
tional effect of antibodies directed against these determi-
nants is classified only as "leading to biological activity",
not necessarily protectivity. For our purposes we consider
this close enough an approximation. This dataset can be
found in the supplementary materials [see Additional file
1].
Calculation of validation characteristics and Machine-
Learning
Validation results were analyzed using the ROCR pack-
age)[44] where specifically AROC (area under the curve of
true-positive rate versus false-positive rate plots) calcula-
tion has been most relevant.
The WEKA package [45] was used where machine-learn-
ing functions were needed, in particular a C4.5 and a Ran-
dom Forest implementation.
Synthesis Score
From a practical point of view predictions of continuous
epitopes should be measured by the number of synthe-
sized peptides required to cover known epitopes. The Syn-
thesis Score is defined as the number of peptides required
to cover at least five epitopic amino-acids in the protectiv-
ity validation dataset. Five has been selected as a mini-
mum requirement for an epitope.
Machine Learning datasets
To analyse the relevance of the used parameters simple
machine learning techniques were applied as imple-
mented in the WEKA package. For these analyses a dataset
was generated based on the entire protectivity dataset (i.e.
not the antigenicity dataset) after exclusion of likely inac-
cessible regions. Essentially all residues which were likely
immune-accessible according to the rules mentioned ear-
lier were represented by the sum score (individually
rescaled between 0 and 1 for each protein), antigenicity,
PTM pattern conservation and variability. This dataset of
dimension 21293 with 1485 antigenic (protective) and
19808 non-antigenic residues (baseline prediction
6.97%) will be termed complete machine learning set
(CML set). In a second step for each antigenic (protective)Immunome Research 2008, 4:1 http://www.immunome-research.com/content/4/1/1
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residue a non-antigenic residue was randomly sampled to
obtain an equilibrated set. This set was then randomly re-
sampled into two stratified sets representing 80% and
20% of CML for training and validation, respectively. The
training set (2376 instances) and validation set (594
instances) are termed MTS and MVS, respectively.
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